A Phase Ia/Ib Study to Evaluate the Safety, Tolerability and PK of MH004 Topical Cream in Healthy Adult Volunteers and to Investigate Its Efficacy and Safety Profile in Participants With Atopic Dermatitis or Rheumatoid Arthritis
Latest Information Update: 06 Mar 2023
At a glance
- Drugs MH 004 (Primary)
- Indications Atopic dermatitis; Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Minghui Pharmaceutical (Shanghai)
- 30 Mar 2021 New trial record